RxDoctor Payments Data

Jignesh Sheth

Internal Medicine · Jermyn, PANPI 1649418369

Payments from drug & device makers

$779in general payments, 2019–2025

Across 42 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$210
  • AbbVie$157
  • Indivior Inc.$71
  • Dexcom, Inc.$70
  • Pfizer$52
  • Medicines360$50
  • plus $169 from 8 others

What the payments were for

  • Consulting fees$506%
  • Food & beverage$71492%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$779 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,568
Medicare patients
79
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$105,241
OzempicSemaglutide65$76,820
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/728$33,078
MounjaroTirzepatide26$28,008
RybelsusSemaglutide14$26,106
AbrysvoRsv Vacc, Pref A And Pref B/Pf67$21,334
ProliaDenosumab11$18,530
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$16,998
ShingrixVaricella-Zoster Ge/As01b/Pf66$14,612
Spiriva HandihalerTiotropium Bromide13$10,260
Novolog FlexpenInsulin Aspart18$5,456
Breo ElliptaFluticasone/Vilanterol11$5,185
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,026
MovantikNaloxegol Oxalate12$4,904
HumalogInsulin Lispro11$4,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$52$126,575228 claims
Novo NordiskOzempic, Rybelsus$17$102,92679 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$15$36,794104 claims
AmgenProlia$33$18,53011 claims
AstraZenecaSymbicort$14$4,00014 claims
AbbVieSynthroid$157$1,47919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Jermyn

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →